Cryopreserved Amniotic Membrane Grafting as Novel Treatment Option for Ocular Surface Dysfunction Associated With or Due to Dry Eye
Purpose
To determine the utility of cryopreserved amniotic membrane grafts (PROKERA©) as a treatment option for patients manifesting superficial punctate keratopathy (SPK) associated with or due to dry eye disease (DED)
Methods
Design:Retrospective chart review
Participants: Persons with SPK associated with or due to DED that was resistant to previous dry eye treatment modalities.
Main Outcome Measures: Resolution of SPK after amniotic membrane graft removal
Results
The total number of patients was 39. The average patient age was 77 years old. The oldest patient was 91, the youngest was 55. The average time of treatment for long-standing/resistant SPK, before presenting to our clinic for amniotic membrane graft treatment, was 294 days. The average BSCVA before treatment was 20/175. 94.9% (37 of 39 patient) of individuals had complete resolution of SPK after an average of 5.3 days of treatment. The average BSCVA after treatment was 20/57.
Conclusion
Cryopreserved amniotic membrane grafting is an option for the treatment of SPK associated with or due to dry eye. This option resulted in improved vision and was a successful treatment modality for those with a history of long-standing or resistant disease.